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Long-term complications and associated conditions of type 1 Gaucher Disease (GD) can include splenectomy, bone
complications, pulmonary hypertension, Parkinson disease and malignancies. Enzyme replacement therapy (ERT)
reverses cytopenia and reduces organomegaly. To study the effects of ERT on long-term complications and
associated conditions, the course of Gaucher disease was modelled.
The cohort consisted of all diagnosed GD patients in the Netherlands. Mutually exclusive disease states were
defined as ‘asymptomatic’, ‘signs/symptoms’, ‘recovery’, ‘splenectomy’, ‘bone complication’, ‘multiple complications’
and ‘malignancy’. A natural history (NH) cohort was delineated based upon historical data on Dutch patients before
ERT was available. Cumulative incidence curves were composed for progression from each disease state to the
next. Two scenarios were applied for the ERT cohort: time to complications was calculated from A. start of ERT;
B. entering the previous disease state.
Median time for the development of signs and/or symptoms was 30.1 years (N = 73). In the NH cohort (N = 42),
9% had developed a bone complication after 10 years in the signs/symptoms phase, while 21% had undergone a
splenectomy. In the ERT cohort (N = 29 (A), N = 28 (B)), 12% (A) or 4% (B) had developed a bone complication after
10 years in this phase and no patient was splenectomized. No patients in the NH cohort recovered, compared to
50% in the ERT cohort after 3.6 years (N = 28 (A)) or 22.4 years (N = 27 (B)) of treatment. Median time from a first to
a second complication was 11 years in the NH cohort (N = 31), whereas 16 respectively 14 percent had developed
a second complication after 10 years in the ERT cohort (N = 17, scenario A/B). Fourteen percent (scenario A/B)
developed an associated malignancy after 10 years in the phase ‘multiple complications’ (N = 23). Associated
malignancies occurred almost exclusively in advanced disease stages, therefore it is suggested that ERT reduces
their incidence
Long-term ERT for GD can reduce the incidence of splenectomy and bone complications. As ERT prevents
progression to more advanced stages of GD it will most likely result in a reduction of associated malignancies.Background
Gaucher disease (GD; OMIM#230800) is an autosomal
recessively inherited lysosomal storage disorder. GD re-
sults from a deficiency of the lysosomal enzyme gluco-
cerebrosidase (or acid β-glucosidase, EC 3.2.1.45). The
enzyme is encoded on chromosome 1 (1q21) and as a
consequence of the deficiency storage of its substrate,
glucocerebroside, occurs in macrophages. These lipid* Correspondence: c.e.hollak@amc.uva.nl
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article, unless otherwise stated.laden cells are called Gaucher cells and are primarily
found in liver, spleen and bone marrow. GD type 1 is
most common in the Ashkenazi Jewish population with
an estimated birth prevalence of 1 per 855 [1]. The over-
all frequency of GD is much lower with an estimated
prevalence in the population of 1 per 100.000. This can
be an underestimation since several patients may re-
main undiagnosed. Three types of GD have been des-
cribed. Type I GD (GD I), the most common phenotype,
can be distinguished from the more severe types II and III
GD based on the absence of the typical neurologic mani-
festations associated with the latter two forms. Clinicalntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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of the accumulation of Gaucher cells in the liver, spleen
and bone marrow compartment, leading to cytopenia, or-
ganomegaly and bone disease. Bone disease in turn, may
present itself as atypical bone pain, severe bone crises or
aseptic osteomyelitis, osteonecrosis, pathological fractures
or vertebral collapse.
The course of GD including the age of onset of signs
and/or symptoms may be influenced by precipitating fac-
tors i.e. Epstein-Barr virus infections or pregnancy [1,2].
Long-term complications and associated conditions of
GD I include liver complications with fibrosis or cir-
rhosis, an increased risk of associated malignancies in-
cluding multiple myeloma and hepatocellular carcinoma
[3,4], Parkinson disease [5,6] and pulmonary hyperten-
sion [7,8]. Up until the early nineties, treatment of GD
consisted purely of supportive measures such as blood
transfusions in cytopenic patients and orthopaedic pro-
cedures in case of bone complications. Splenectomy was
the only possible intervention in case of severe spleno-
megaly and cytopenia. However, it soon became appar-
ent that splenectomy had a negative impact on bone
involvement and accumulation of Gaucher cells in the
liver [4,9-12].
Since the early nineties therapy has become available
in the form of purified enzyme, placental derived al-
glucerase later replaced by recombinant imiglucerase
(Genzyme Corp, MA, USA) for the treatment of GD I
and visceral manifestations of GD III. In 2002 substrate
reduction therapy in the form of miglustat (Actelion
Therapeutics) received marketing authorization. Miglustat
is an inhibitor of glucosylceramide synthase and received
authorization for the treatment of mild to moderate
Gaucher disease. In 2010 velaglucerase alfa, another en-
zyme preparation (Shire Human Genetic Therapies, MA,
USA) was approved for long-term treatment of GD I.
New therapies are still emerging as taliglucerase alfa, yet
another recombinant enzyme (Protalix, Biotherapeutics,
Carmiel, Israel) has completed phase 3 clinical trials and
has received authorization in the USA and Israel. An alter-
native, oral inhibitor of glucosylceramide synthase, eliglu-
stat tartrate, is currently in the late stages of clinical
development [13,14].
Enzyme replacement therapy has been shown to be
highly effective in reversing cytopenia and reducing or-
gan volumes (see for example [15-21]). Controversy exists
regarding its effect on bone disease, as this compartment
seems slower to respond and skeletal disease may be par-
tially unresponsive to therapy especially in a patient with a
history of extensive bone manifestations before the initi-
ation of treatment [22].
Besides these effects, beneficial effects on quality of life
have been demonstrated [23-27]. Both substrate reduction
therapy and enzyme replacement therapy are extremelycostly with variations in costs depending on the agent and
dose. Variations in dose exist between countries. Median
dose in the Netherlands is 30 U/kg/month (range 15–
120 U/kg/month), but doses up to 120 U/kg/m are
prescribed internationally.
So far, cost-effectiveness analyses have not been per-
formed. Connock addressed cost-effectiveness of several
enzyme replacement therapies and concluded that the
available data were insufficient to draw a conclusion [28].
The main limitations were the absence of natural history
data and reliable information on quality of life. Real life
experience with enzyme replacement therapy, mainly imi-
glucerase, suggests that when started early, i.e. before irre-
versible damage has occurred, ERT may prevent both the
the need for splenectomy and the incidence of bone di-
sease. Whether long-term complications and associated
conditions of GD I can be prevented is debated [12,29].
This is surprising, because ERT is already available in
Western countries for 20 years. To address the issue of ef-
fects of ERT on long-term complications and associated
conditions, we studied the progression of Gaucher disease,
which can be used in a state transition model to assess the
cost-effectiveness of Gaucher disease treatments. Such
model is reported elsewhere in this journal [30].
Patients and methods
This study was part of the TIPharma project T6-208: Sus-
tainable Orphan Drug Development through Registries
and Monitoring.
The Academic Medical Center is a national referral
center for patients with Gaucher disease. This cohort
consisted of all registered Gaucher disease patients in
the Netherlands with a definite diagnosis of Gaucher
disease based upon analysis of enzymatic activity and
mutation analysis. Historical data were collected from
all patients for whom a medical record before ERT was
available (April 1991). For all patients who started ERT
in the Netherlands after April 1991, prospective data
were collected up to September 1, 2011.
Patient cohorts
A natural history cohort and an enzyme replacement
therapy (ERT) cohort were defined as follows:
NH cohort
Enzyme replacement therapy became available in the
Netherlands in April 1991. Historical data on the pro-
gression of disease were retrieved from clinical records
in all 90 patients. For the assessment of the time to onset
of signs and/or symptoms the entire AMC cohort was an-
alyzed, since only symptomatic patients are treated.
For the assessment of each consecutive disease stage
only patients who had reached a particular disease stage
before the era of ERT were included in the analysis. The
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after ERT became available would lead to an underes-
timation of disease progression as a result of bias by
indication, as these patients exhibit milder disease ma-
nifestations. Thus, patients who had reached a particular
disease stage prior to April 1991 were included in the ana-
lysis of the natural course of progression from that par-
ticular disease stage to the next, e.g. from signs and/or
symptoms to bone complications. If a patient showed no
progression before April 1991, then April 1991 was noted
as the end of follow-up and the case was censored.
ERT cohort
Prospective data were collected from patients who were
treated with ERT at the AMC (n = 64). In addition, the
analysis included data from 2 patients who started treat-
ment with ERT elsewhere. The data were retrieved from
the start of ERT up to September 2011. Patients who
switched from ERT to SRT (N = 2) data were included
until the moment of switch. In patients who started
treatment with substrate reduction therapy (N = 3) data
were only included for the analysis of the natural course
of disease (until the moment treatment with SRT was
commenced). All patients have suffered from the world-
wide imiglucerase shortage (June 2009). No distinction
was made between patients who switched to treatment
with either velaglucerase alfa or taliglucerase alfa as a re-
sult of the shortage. In addition, the consequences of dose
reductions as a result of the shortage were not taken into
account, as signs of deterioration were short-lived and did
not affect the assignment of patients to categories of dis-
ease severity.
Definition of disease states
To model the course of Gaucher disease, mutually ex-
clusive disease states were defined as follows:
Signs/Symptoms
Most patients had developed signs and/or symptoms
prior to the start of follow-up at the Academic Medical
Center in 1991 or later. A record of signs/symptoms, cy-
topenia or organomegaly in the medical history was used
as a criterion for the signs/symptoms stage. Patient files
were scanned for any record of increased bleeding ten-
dency, abnormalities in blood counts and/or organome-
galy either upon physical examination or imaging. The
date of onset of signs and/or symptoms was recorded
as exactly as possible. If only the year in which signs
and/or symptoms had occurred was recorded, the date
was set for the first of January of that year. If only
the age was mentioned, the date was set for the first
of January of the year in which a patient reached that
particular age.Splenectomy
If a patient was splenectomized, the date at which a
splenectomy had been performed was recorded. If only
the month and year in which a patient was splenecto-
mized were reported the date was set for the first of that
specified month. If only the year in which a patient was
splenecomized was recorded the date was set for the
first of January of that year.
Bone complications
Bone complications were narrowly defined by the occur-
rence of osteonecrosis, pathological fractures, vertebral
collapse, osteomyelitis, and/or bone crises/infarctions.
A bone crisis was defined as an episode of severe pain
localized in a bone (no joint), requiring opioids and/or
hospitalization, and/or accompanied by signs of inflam-
mation (e.g. fever), and/or imaging abnormalities (X-ray,
magnetic resonance imaging). For most patients, bone
complications had started long before their first presenta-
tion at the AMC. The exact date of onset of bone com-
plications was recorded as precisely as possible. Again, if
only the year in which a complication had occurred was
recorded then the date was set for the first of January of
that year.
Multiple complications
If a patient had experienced multiple bone complications
separated by a symptom free interval, again according to
the previously stated definitions, the date of their second
bone complication was recorded. Parkinson disease and
pulmonary hypertension were included as associated con-
ditions in this phase.
Malignancy
Malignancies associated with Gaucher disease were de-
fined as: multiple myeloma, AL amyloidosis, which is as-
sociated with monoclonal plasma cell proliferation or
hepatocellular carcinoma. The starting date was chosen
as the first occurrence of signs and/or symptoms associ-
ated with this condition.
Recovery
Date of resolution of signs and/or symptoms: unless ex-
plicitly stated otherwise, it was assumed that if signs
and/or symptoms such as anemia had started prior to
follow up at the AMC and were present at first presenta-
tion, they had been present in the meantime. Signs and/
or symptoms were said to be resolved if:
1. Hb levels >13.5 g/dl (8.4 mmol/L) in men and >12 g/dl
(7.5 mmol/L) in women (American Society of
Hematology (ASH));
2. Platelet count was >100*10E9/L [31], for one year
(if this was the case, then the date of the first
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if follow-up ended before a year was reached then
no date of resolution was recorded);
3. Liver volume was <1.25 multiples of normal (MN)
and spleen volume was below 5 MN at two
consecutive measurements [32] (no minimum for
this interval was defined, in practice patients are
evaluated 1–2 per year, the first measurement was
recorded as the date of resolution);
4. A bone marrow fat fraction Ff as assessed by Dixon’s
Quantitative Chemical Shift Imaging >23% at two
consecutive measurements.
Figure 1 represents a multi-state diagram of our mo-
del. Please note that the corresponding model is depicted
in Figure 1 of our manuscript on the cost-effectiveness of
ERT for GD [30].
Statistical analysis
Survival analysis was applied to study the time to pro-
gress to the next disease stage (e.g. from signs/symptoms
to bone complications), while censoring patients at the
end of their follow-up if they did not progress. It is gen-
erally assumed that censoring is non-informative. How-
ever, when patients may progress to one of multiple next
disease stages (e.g. bone complications or splenectomy),
then the patient may never progress to the disease stage
of interest (bone complications), because of progressing
to the other first (splenectomy), thus changing his prob-
ability of developing bone complications. If so, censoring
for bone complications would be informative and en-
tering the stage of splenectomy should be considered aFigure 1 Multi-state diagram of our proposed model. Please note that
cohort, with two exceptions: 1: recovery was not observed in the NH coho
patients are not treated.competing risk event. The common Kaplan-Meier ap-
proach to survival analysis is not appropriate here [33].
Instead, a competing risk analysis was applied with data
represented by a cumulative incidence curve for each
next disease stage separately.
For consistency, data were also represented by cumu-
lative incidence curves in absence of competing risks
(including the 95% confidence intervals), except for an
overall analysis of time till death in our cohort (irre-
spective of treatment status, treatment duration, and
cause of death), when the usual Kaplan-Meier survival
approach was applied.
A cumulative incidence curve was composed for the
time to development of signs and/or symptoms in the
NH cohort, with progression to bone complications as a
competing risk.
Cumulative incidence survival curves were composed
for both the NH and the ERT cohort for:
– time from signs and/or symptoms to a bone
complication, with progression to splenectomy as
competing risk
– time from signs and/or symptoms to (the need for) a
splenectomy, with progression to a first bone
complication as a competing risk
– time from a splenectomy to a bone complication
(progression to the phase ‘multiple complications’)
– time from the first bone complication to progression
to the phase ‘multiple complications’ (the
occurrence of either a second bone complication or
the need for a splenectomy), with progression to a
malignancy as a competing riskthis diagram represents both the NH chohort as well as the ERT
rt. 2: the ERT cohort has no asymptomatic state as asymptomatic
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the progression to bone complications or a
splenectomy as competing risks
For the ERT cohort, cumulative incidence curves were
drawn for 2 different scenarios. Since patients started
treatment at different disease stages, the occurrence of a
complication soon after start of treatment would not ne-
cessarily give a reliable estimate of the effect of therapy.
To address this, the scenarios were as follows:
– In scenario A (depicted in Figures 2a, 3a, 4a, 5a and 6a),
start of follow-up for each disease state was calculated
from the date a patient started ERT.
– In scenario B (depicted in Figures 2b, 3b, 4b, 5b
and 6b), the start of follow-up for each disease
state was adjusted to the date a patient entered
that stage (and not the date at which ERT was
started), which means that some events took
place at a later time point as compared to
scenario A.
Patients in the signs/symptoms stage can recover as a
result of ERT. For the analysis of progression from signs
and/or symptoms to complications, the end of follow-up
of these patients was adjusted to include the phase “re-
covery” and the stage that followed was adjusted to the
stage that followed the phase “recovery”, i.e. if a patient
recovered from signs and/or symptoms, but nonetheless
developed a bone complication, the duration of follow-
up in the signs/symptoms stage included both the signs/
symptoms phase and the recovery phase and the patient
was said to have experienced the event in the survival
analysis for progression from signs and/or symptoms to
bone complications.
Please note that this approach differs from the ap-
proach adopted in our accompanying paper on the cost-
effectiveness analysis [30]. In this paper, “recovery” was
treated as a separate stage in order to calculate the tran-
sition probabilities used in the Markov model. However,
in the current paper all analyses are depicted as survival
curves, which would lead to an overestimation of the
chance of progression from “signs/symptoms” to “compli-
cations” as patients who recover are filtered out, leaving
those patients who remain in the state “signs/symptoms”
or those who experience a complication.
Results
For ninety GD I patients clinical records or prospective
data were available.
Figures 7, 8 and 9 represent the numbers of patients in each
of the different disease stages for the NH and ERT cohort
respectively. All percentages reported concern percentages
derived from the survival analysis corrected for competingrisks. All events that could be construed as competing risks
for a specific analysis that occurred are mentioned below.
Calculations of Progression or Recovery
Progression from asymptomatic to signs/symptoms
Of 90 patients, clinical records were available for 77 pa-
tients to determine the date of onset of signs and/or
symptoms. Four patients did not qualify for the analysis
of progression from asymptomatic to signs/symptoms:
2 patients who remained asymptomatic during follow-up
and 2 patients who started treatment while they were
asymptomatic. Of 73 asymptomatic patients, six deve-
loped a bone complication as the first disease manifestation
and 67 developed cytopenia or organomegaly consistent
with the predefined signs/symptoms stage. Median time to
progression, corrected for bone complications as a compet-
ing risk was 30.1 years. Figure 10 depicts the cumulative
incidence curve. No separate analysis for patients from the
NH or ERT cohort is made, since asymptomatic patients
are not eligible for treatment in the Netherlands.
Progression from signs/symptoms to complications,
NH cohort
Of 67 patients, 42 had developed signs and/or symp-
toms prior to April 1991. Twenty-six patients showed
no progression before April 1991, 4 developed a bone
complication and 12 underwent a splenectomy. Nine
percent had developed a bone complication after 10 years
in the signs/symptoms phase, whereas 21 percent had
undergone a splenectomy after 10 years in the signs/
symptoms phase.
Progression from signs/symptoms to complications,
ERT cohort
Twenty-nine patients started treatment in the signs/symp-
toms stage, i.e. before complications occurred.
Scenario A: of 29 patients, 25 showed no progression
during follow-up. One patient died as a result of a renal cell
carcinoma after recovery of signs/symptoms of Gaucher
disease. Four patients with signs/symptoms developed a
bone complication while treated. In one patient this bone
complication occurred after recovery from signs/symptoms.
Twelve percent had developed a bone complication after
10 years in the signs/symptoms phase. No patient in
the ERT cohort underwent a splenectomy.
Scenario B: Of 28 out of the 29 above-mentioned pa-
tients a reliable record of onset of signs and/or symptoms
was available. Twenty-four showed no progression during
follow-up. One patient died as a result of a malignancy
unrelated to Gaucher disease. Four patients with signs/
symptoms developed a bone complication while treated.
In one patient this bone complication occurred after she
recovered from signs and/or symptoms. Four percent had
developed a bone complication after 10 years in the signs/
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Figure 2 Cumulative incidence of bone complications in untreated and treated patients with signs/symptoms. a. scenario A, untreated
N=42, treated N=29, b. scenario B, untreated (N = 42), treated (N = 28).
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Figure 3 Cumulative incidence of spenectomies in untreated and treated patients with signs/symptoms. a. Scenario A, untreated N = 42,
treated N = 29 b. Scenario B, untreated N = 42, treated N = 28.
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Figure 4 Cumulative incidence of recoveries in untreated and treated patients with signs/symptoms. a. Scenario A, untreated (N = 42),
treated (N = 28). b. Scenario B, untreated N=42, treated N=27.
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Figure 5 Cumulative incidence of second complications in untreated and treated patients with a first complications. a. Scenario A,
untreated N=31, treated N=17 b. Scenario B, untreated N = 31, treated N = 17.
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Figure 6 Cumulative incidence of malignancies in treated patients with multiple complications. a. Scenario A, N=23 b. Scenario B, N=23.
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Figure 7 Flow-chart of the NH cohort. Please note that two patients who remained asymptomatic during follow-up were excluded from the
analysis as both patient where diagnosed because of family studies. Two patients who started treatment while asymptomatic where excluded
because the reasons/circumstances for starting treatment differed from other patients (e.g. patients’ wish).
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a splenectomy while treated.Progression from signs/symptoms to recovery, NH cohort
No patient in the NH cohort recovered.Progression from signs/symptoms to recovery, ERT cohort
Twenty-nine patients started treatment in the signs/
symptoms stage, i.e. before complications occurred. One
patient had started treatment elsewhere and was transitioned
to our center after he had recovered. The date of recovery
could not be assessed in this patient.
Figure 8 Flow-chart of the ERT cohort, start of follow-up = start ERT.
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or symptoms. Fifty percent had recovered after 3.6 years
of treatment (median time to recovery).
Scenario B: of 27 out of the 28 above mentioned
patients a reliable record of onset of signs and/orsymptoms was available, 18 recovered from signs/symp-
toms. Fifty percent had recovered after 22.4 years.
Figures 2a-b and 3a-b represent the cumulative incidence
curves for the NH and ERT cohort for progression from
signs/symptoms to bone complications and splenectomy,
Figure 9 Flow-chart of the ERT cohort, start follow-up = start phase (in contrast to start ERT).
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recovery in the NH and ERT cohort.Progression from a first complication to a second
complication, NH cohort
Eleven patients had experienced a bone complication be-
fore April 1991. These include 4 patients who progressed
from the signs/symptoms phase to bone complications
and 5 patients who were diagnosed following a bone com-
plication as the first manifestations of disease. In addition,
2 patients were diagnosed after a bone complication
occurred and were found to display signs/symptoms at
that time.
In eight patients a second complication occurred.
Twenty patients were splenectomized before April 1991.
In eleven patients a bone complication occurred before
April 1991. Median time from the first to the second com-
plication was 11 years.Progression from a first complication to a second
complication, ERT cohort
Thirteen patient started treatment after a first complica-
tion had occurred (N = 7 after a splenectomy, N = 6 after
a bone complication). In addition four patients had de-
veloped a bone complication while treated.
Of 10 patients who had experienced a single bone
complication and received treatment, 8 showed no pro-
gression and 2 developed a second complication.
Of seven patients who started treatment after having
been splenectomized, 1 patient developed a malignancy
while treated (a hepatocellular carcinoma), 6 patients
showed no progression.
One patient developed pulmonary hypertension, while
already in the phase multiple complications. Signs of
pulmonary hypertension had been present before the
start of ERT. Another patient was diagnosed with Par-
kinson disease while already in the phase multiple
complications. This patient had been receiving ERT forTable 1 Characteristics of 9 GD patients who developed a GD
Complication Treatment status at diagnosis
Amyloidosis/MM ERT <2 years
HCC ERT <2 years
Amyloidosis/MM untreated
HCC ERT 6 years
Amyloidosis/MM ERT 2 years
Amyloidosis/MM ERT 15 years
HCC ERT >17 years
Amyloidosis/MM ERT 19 years
HCC ERT 18 yearsmore than 13 years at the time of the diagnosis Parkinson
disease.
Figures 5a-6 depict the cumulative incidence curves from
a first complication to the phase ‘multiple complications’.
In scenario A sixteen percent had experienced a sec-
ond complication, 10 years after a first complication.
In scenario B fourteen percent had experienced a sec-
ond complication 10 years after a first complication had
occurred.
Malignancy
Nine patients in the entire Dutch cohort had developed
a Gaucher associated malignancy. Characteristics of these
patients are included in Table 1. One patient was treatment
naive when a diagnosis of multiple myeloma was made,
3.1 years after a splenectomy had been performed. Since
this diagnosis was made after April 1991 this case was ex-
cluded from the NH cohort. As previously described, one
patient developed a hepatocellular carcinoma 22.4 years
after a splenectomy (6.1 years after start of ERT).
Seven patients developed an associated malignancy after
having experienced multiple Gaucher related complica-
tions; 3 patients developed a hepatocellular carcinoma
(all were splenectomized) and four patients devel-
oped a multiple myeloma (of whom 2 were splenecto-
mized). Figure 6a-b depict the cumulative incidence
curves for progression from multiple complications
to malignancy.
In scenario A fourteen percent had developed a ma-
lignancy 10 years after having started treatment in the
phase multiple complications.
In scenario B fourteen percent had developed a malig-
nancy 10 years after their second complication.
A survival curve of the entire study cohort, irrespec-
tive of treatment status is presented in Figure 11.
Discussion and conclusion
Numerous studies have shown that enzyme replacement
therapy for Gaucher disease is effective in reversing signs/associated malignancy
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Figure 10 Cumulative incidence of signs/symptoms in asymptomatic patients (N = 73).
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example [15-21]). Studies have also shown that the effects
on signs/symptoms are accompanied by improvements in
quality of life (QoL) [23-27]. The study by Damiano et al.
shows that a history of splenectomy and joint replacement
was associated with a decrease in QoL. The study by
Giraldo et al. supports this, but did not find an asso-
ciation between degree of cytopenia and QoL. Given this
high impact of long-term complications and associated
conditions of Gaucher disease on QoL, it is important to
investigate the effect of ERT on the incidence of these
events. In addition, from a cost-effectiveness perspective,
the question whether ERT can prevent morbidity is valid
as well, since treatment is very expensive.
As expected, a large proportion of ERT treated patients
recovered from a signs/symptoms state to an asymptom-
atic state. None of the patients in our historic NH cohort
recovered spontaneously. We have reported earlier that
mildly affected patients may show some degree of spon-
taneous improvement [34], but for the more severely
affected NH cohort patients in the current study, an
improvement that would reclassify them to the asymp-
tomatic stage was not observed.
Progression from the signs/symptoms stage to the de-
velopment of complications was positively influenced by
ERT. First, we studied the effect of enzyme replacement
therapy on the need for a splenectomy. Severe cytopenia
due to functional hypersplenism and mechanical pressurecausing abdominal complaints may both necessitate a
splenectomy. Since ERT has been shown to effectively re-
duce splenomegaly and cytopenia one might assume that
splenectomies in the ERT era are rarely indicated. Indeed,
our study shows significant differences in the incidence of
this complication in the NH cohort when compared to
the ERT cohort. In fact, none of the treated patients
underwent a splenectomy. However, there are anecdotal
reports to suggest that ERT might not be able to prevent
the need for a splenectomy in rare circumstances such as
the development of neutralizing antibodies to ERT (Ponce
et al. 1997) or extensive fibrosis (Krasnewich et al. 1998)
rendering a patient irresponsive to treatment [35,36].
Bone complications are another important group of
(long-term) complications in GD I that have an import-
ant impact on the quality of life of patients [23,24,27].
The effect of ERT on bone complications is slightly more
controversial. Several studies show that ERT improves im-
aging parameters thought to reflect a patient’s risk of de-
veloping bone complications. These include the Rosenthal
staging system [37], Quantitative Chemical Shift Imaging
(QCSI) measurements [37-39], the Düsseldorf marrow
disease score [40], and Bone Marrow Burden (BMB)
scores [41]. The effect of ERT on bone mineral dens-
ity measurements is more controversial [42-45]. While
an effect of ERT on these markers is important to note,
clearance of Gaucher cells from the bone marrow does
























all all 95% LCL all 95% UCL
Figure 11 Cumulative survival in the entire study cohort, irrespective of treatment status, treatment duration, and cause of death
(N = 90). Red lines represent the NH cohort, black lines represent the ERT cohort. LCL: lower confidence limit. UCL: upper confidence limit.
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tients, clearance of Gaucher cells from the bone marrow
poses less risk to patients for development of bone com-
plications [47]. Other studies have attempted to quantify
the effects of ERT on clinical bone disease describing posi-
tive effects on bone pain and/or a reduction in the fre-
quency of bone events in ERT treated patients [48-52].
These studies are supported by data from the Gaucher
Registry [53,54] including a recent study by Mistry et al.,
which shows that patients who initiated ERT within 2 years
of diagnosis had a significantly reduced risk of developing
osteonecrosis compared to those who started more than
2 years after their diagnosis [55]. This may not seem
surprising as the latter group consisted of patients with
more pretreatment bone disease, developed before ERT
was available. The data presented here are derived from
the entire Dutch cohort and the natural history data were
carefully selected to avoid limitations such as bias by indi-
cation. It offers further evidence that ERT can significantly
reduce the frequency of bone complications, but cannot
fully prevent these. The two scenarios that were employed
show the largest difference for the occurrence of bone
complications: 12% or 4% within 10 years of ERT for sce-
nario A and B respectively. Within scenario A, patients
could develop a bone complication quite quickly after
start of ERT, as their time to complication was calculated
from start of ERT. It is questionable whether this gives a
realistic estimate of the effect of ERT. To overcome this,
we calculated the time between the occurrence of a com-
plication and the start of the previous disease state. Thismay give a more reliable estimate of the time to develop a
complication, although the most optimal effect of ERT to
reduce the occurrence of bone complications can only
be assessed in a situation where only early symptomatic
patients, without a history of bone complications, enter
the model.
Finally, we studied the incidence of Gaucher associated
malignancies. These malignancies occurred almost ex-
clusively in the ERT treated patients. However, associated
malignancies are certainly not a consequence of treatment
as evidenced by numerous studies and case reports de-
scribing the occurrence of these malignancies in untreated
patients (see for example Lee et al. [56]). The reason for
the absence of malignancies in the natural history cohort
is obviously caused by the fact that clinical records were
only available from patients who had visited our center at
least once after April 1991, and those with associated ma-
lignancies had probably died earlier. Our data illustrate
that malignancies occur mostly in patients with advanced
Gaucher disease, which would have provided patients with
a clear indication to start treatment. Our study is thus
subject to a certain selection bias, as patients with associ-
ated malignancies are underrepresented in our NH cohort,
which might underestimate the effect of ERT. Furthermore,
age is an important determinant of cancer risk. Our treated
cohort consists largely of patients from the NH cohort that
have aged and this will have influenced cancer incidence.
By showing that ERT effectively prevents/reduces progres-
sion to more advanced stages of disease, it is suggested that
ERT is able to reduce the frequency of Gaucher associated
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hepatocellular carcinoma in GD I patients is exclusively
seen in splenectomized patients and splenectomies were
only performed in untreated patients, and 2) only one pa-
tient developed an MGUS, while treated. MGUS in itself is
not a malignancy, but in the general population the yearly
risk of transition from an MGUS to a multiple myeloma or
other lymphatic malignancy is 1% [57].
However, some caution with regard to the effect of
ERT on malignancies is warranted as they represent a
heterogeneous group. While the occurrence of HCC has
thus far only been reported in patients with advanced
GD [9], multiple myeloma has been reported in patients
displaying mild disease (i.e. [58]) and its association with
disease severity or extent of residual disease may be less
straightforward.
Furthermore, with regard to the hepatocellular carcin-
oma, while recent evidence suggests an increased risk in
GD patients [9,59], literature on its pathophysiology is
limited and this aspect deserves further study [10].
The retrospective design of this study is an important
limitation. Data on signs/symptoms and complications and
associated conditions may not have been recorded as ri-
gorously as would have been the case in a prospectively
designed study. Consequently, the rate of disease progres-
sion in untreated patients has possibly been underesti-
mated in the present analysis. At the same time, disease
progression among patients receiving ERT has probably
been overestimated, because many patients already had
spent some time in the disease stage before ERT became
available on the market in 1991; this delayed start with
ERT may have resulted in suboptimal treatment. This is a
particular limitation for scenario A, in which previous time
spent in the disease state is ignored. Therefore scenario B
was developed in which this time was added to the time
on treatment in the specific disease stage. However, this
scenario may still lead to an overestimation of the rate of
disease progression under ERT since ERT has in fact not
been given during the entire disease stage. On the other
hand, both scenarios are subject to “immortal time bias”:
only patients who were alive and in the disease state under
study at or after the introduction of ERT are included,
which may result in an underestimation of disease progres-
sion. While both scenario’s are artificial, these effects may
balance each other to some extent. Statistical approaches
with ERT use as a time-varying covariate (e.g. Cox regres-
sion) would also be worth studying in order to assess the
impact of potential misclassification and selection biases.
Given the variations in dosing regimens worldwide, it
is of interest to discuss the effect of ERT dose on disease
progression and incidence of long-term complications
and associated conditions. A previous study showed that
high dose ERT results in faster and more pronounced
responses in plasma chitotriosidase activity and bonemarrow involvement [60]. A subsequent study from the
Gaucher Registry confirmed a dose effect on clinical pa-
rameters [61]. One might hypothesise that high dose
ERT results in a more effective prevention of long-term
complications and associated conditions. However, the
relationship between the extent of residual disease and
the risk for long-term complications and associated con-
ditions remains unclarified.
In conclusion, long-term enzyme replacement therapy
for Gaucher disease can effectively reduce the incidence
of splenectomy and bone complications, and will most
likely result in a reduction in the risk of developing
malignancies
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